July 16 Financial Quick Takes: J&J growth drivers beat consensus; plus Notable and Cradle raise funds

Imbruvica, Darzalex sales top analysts' consensus
In its 2Q19 earnings report, Johnson & Johnson (NYSE:JNJ) said revenue from its pharmaceutical

Read the full 198 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE